37 results about "Radiosynthesis" patented technology

Macro- and microfluidic devices and related technologies, and chemical processes using such devices. More specifically, the devices may be used for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in an efficient, compact and safe to the operator manner. In particular, embodiments of the present invention relate to an automated, multi-run, microfluidic instrument for the multi-step synthesis of radiopharmaceuticals, such as PET probes, comprising a remote shielded mini-cell containing radiation-handing components.

Methods and apparatus enable radiosynthesis of radiolabeled compounds using electrochemical trapping and release. The trapping and release of radioactive isotopes all occur inside a microreactor, a vial or similar device, thus eliminating the need for azeotropic drying and several dead-end filling steps, as well as the necessity to move concentrated radioisotopes from one compartment of the chip to another. These and other features allow radioisotope enrichment to be carried out internally within a radiochemical synthesis chip, providing faster and more robust operation, as well as producing very high radiochemical labeling yields.

A microscale solution for conducting [¹⁸F]fluoride phase transfer and subsequent radiosynthesis of 2-[¹⁸F]FDG that eliminates the azeotropic drying process. [¹⁸F]fluoride phase transfer is performed using an inexpensive disposable microchip. Additionally, each subsequent each step may be performed on the same single microchip.

Methods and devices for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in a fast, efficient and compact manner are disclosed. In particular, the various embodiments of the present invention provide an automated, stand-alone, hands-free operation of the entire radiosynthesis cycle on a microfluidic device with unrestricted gas flow through the reactor, starting with target water and yielding purified PET radiotracer within a period of time shorter than conventional chemistry systems. Accordingly, one aspect of the present invention is related to a microfluidic chip for radiosynthesis of a radiolabeled compound, comprising a reaction chamber, one or more flow channels connected to the reaction chamber, one or more vents connected to said reaction chamber, and one or more integrated valves to effect flow control in and out of said reaction chamber.

The invention provides a 2-fluoro-aniline quinazoline compound labelled by F-18, wherein <18>F is produced by a circular accelerator via <18>O(pn)<18>F nuclear reaction and automatically synthesised by a radioactive synthesis module, and can also be produced by the existing domestic F-18 multifunctional synthesis device after process reformation. The 2-fluoro-aniline quinazoline compound provided by the invention is of an aniline quinazoline structure substituted by 2-bit positron nuclide fluorine-18, and can be modified on 6-bit, 7-bit and benzene ring connected with an amino group. The invention provides novel tumour positron imaging agents, wherein compared with <18>F-fluoro-deoxyglucose (<18>FDG), the imaging agents are specific, and capable of identifying the tumours highly expressed by an epidermal growth factor receptor (EGFR). The preparation method is reasonable in design, simple in labelling method, capable of realizing automatic production, and suitable for application. The structural general formula of the 2-fluoro-aniline quinazoline compound is defined in the specification.

The present invention relates to methods of synthesizing ¹⁸F-FMAU. In particular, ¹⁸F-FMAU is synthesized using one-pot reaction conditions in the presence of Friedel-Crafts catalysts. The one-pot reaction conditions are incorporated into a fully automated cGMP-compliant radiosynthesis module, which results in a reduction in synthesis time and simplifies reaction conditions. The one-pot reaction conditions are also suitable for the production of 5-substitued thymidine or cytidine analogues. The products from the one-pot reaction (e.g. the labeled thymidine or cytidine analogues) can be used as probes for imaging tumor proliferative activity. More specifically, these [¹⁸F]-labeled thymidine or cytidine analogues can be used as a PET tracer for certain medical conditions, including, but not limited to, cancer disease, autoimmunity inflammation, and bone marrow transplant.

The present disclosure relates to the novel multistep procedure for preparation of polymer monoliths for use in solvent exchange, such as methods to exchange and activate fluoride ions on a flow through microfluidic chip for subsequent chemical synthesis. Methods according to the present disclosure include the application of such microfluidic platforms for rapid F18 radiosynthesis on a flow through microfluidic chip with high efficiency, followed by a subsequent nucleophilic fluorination reaction. Various other methods of exchanging and activating fluoride ions on a flow through microfluidic chip are also disclosed. Methods incorporating features of the present invention can be applicable to any flow through microfluidic device in any field, such as radiosyntheses, chemical syntheses, concentration of ions for environmental analyses and sample preparation such as concentrating minute amounts of analyte to improve the downstream detection.

The invention relates to 2-<18>F-fluoropropionic acid isomers: R-2-<18>F-fluoropropionic acid (R-<18>F-FPA, formula 1) and S-2-<18>F-fluoropropionic acid (S-18F-FPA, formula 2), a synthesis method and application thereof in preparation of positron emission tomography (PET) imaging agent drugs. Enantiomer R- or S-2-trifluoromethanesulfonic acid-ethyl propionate is adopted as the precursor, and can be obtained by nucleophilic fluorination and hydrolysis two-step reaction. The chiral PET drug radiation synthesis method provided by the invention is simple, has high radiochemical yield, and is convenient for automatic synthesis, and the enantiomers can be used for differential diagnosis and therapeutic effect evaluation of tumors, cardiovascular and cerebrovascular diseases and neuropsychiatric disorders. (formula 1, and formula 2).

The invention relates to an optics and positron emission tomography (PET) dual-mode developer (formula 1) targeted to apoptotic cells and beta-amyloid protein, namely, a positron-nuclide-labeled 4-dansyl amido-4'-diphenylethylene compound. A synthesis method of the compound includes the steps that dansyl targeted to apoptotic cells and 1,2-diphenylvinyl-amino targeted to beta-amyloid protein are bound together, and then labeling is conducted. The compound is simple in radiosynthesis method, high in radiochemical yield and convenient to synthesize automatically, has broad application prospects and can be applied to anti-tumor therapy monitoring and differential diagnosis and scientific research on neurological and psychotic disorders like Alzheimer disease (AD). The formula 1 is defined in the description.

The present invention relates to ¹⁸F radio-chemistry and in particular to a method for synthesising radiofluorinated amides and amines. The method of the invention has particular application in the radiosynthesis of a variety of ¹⁸F-labelled positron emission tomography (PET) tracers.

The invention relates to a tumor positron emission tomography(PET) imaging agent <68>Ga-NOTA-ADG and a preparation method and application thereof, and relates to synthesis of a labeling precursor of the PET imaging agent <68>Ga-NOTA-ADG and radiosynthesis of the <68>Ga-NOTA-ADG, wherein the precursor is used for labeling the <68>Ga-NOTA-ADG for the first time, and a result shows that the radiochemical yield of the preparation method is close to 100%. The positron imaging agent <68>Ga-NOTA-ADG provided by the invention can be used as a PET imaging probe for targeting tumors. Therefore, the <68>Ga-NOTA-ADG becomes a PET candidate imaging probe for the tumors. According to the invention, the radioactive chemical synthesis of the <68>Ga-NOTA-ADG is carried out for the first time, the preparation method is simple and rapid, and a foundation is laid for scientific research and clinical application of the <68>Ga-NOTA-ADG.

Radiolabelled acid chlorides may be synthesised by reacting a radiolabelled carboxylic acid with a solid-phase supported chlorinating agent.